Copyright
©The Author(s) 2025.
World J Clin Cases. Nov 26, 2025; 13(33): 110641
Published online Nov 26, 2025. doi: 10.12998/wjcc.v13.i33.110641
Published online Nov 26, 2025. doi: 10.12998/wjcc.v13.i33.110641
Table 1 Baseline characteristics before matching, n (%)/mean ± SD
| Baseline characteristics | RA+DM (n = 60523) | RA-DM (n = 138848) | P value |
| Age | 69.06 (11.56) | 68.25 (14.41) | < 0.001 |
| Gender | |||
| Female | 42031 (69.45) | 102277 (73.66) | < 0.001 |
| Race | |||
| White | 40840 (67.48) | 108904 (78.43) | < 0.001 |
| Black | 10059 (16.62) | 14765 (10.63) | < 0.001 |
| Hispanic | 6368 (10.52) | 9481 (6.83) | < 0.001 |
| Asian | 1375 (2.27) | 2718 (1.96) | < 0.001 |
| Native | 1196 (1.98) | 1999 (1.44) | < 0.001 |
| Other | 685 (1.13) | 990 (0.71) | < 0.001 |
| Comorbidities | |||
| Gastro-esophageal reflux disease | 21363 (35.3) | 46663 (33.61) | < 0.001 |
| Chronic obstructive pulmonary disease | 7849 (12.97) | 16699 (12.03) | < 0.001 |
| Asthma | 6271 (10.36) | 12672 (9.13) | < 0.001 |
| Smoking | 5780 (9.55) | 15831 (11.4) | < 0.001 |
| Heart failure | 29061 (48.02) | 38053 (27.4) | < 0.001 |
| Chronic kidney disease | 20373 (33.66) | 23650 (17.03) | < 0.001 |
| Atrial fibrillation | 9868 (16.3) | 19183 (13.81) | < 0.001 |
| Ventricular tachycardia | 1065 (1.76) | 1996 (1.44) | < 0.001 |
| Hypertension | 53568 (88.51) | 99210 (71.45) | < 0.001 |
| Obesity | 19604 (32.39) | 25059 (18.05) | < 0.001 |
| Alcohol use | 1132 (1.87) | 4936 (3.55) | < 0.001 |
| Steroids use | 5767 (9.53) | 15274 (11.0) | < 0.001 |
| Coronary artery disease | 21901 (36.19) | 31360 (22.58) | < 0.001 |
Table 2 Baseline characteristics after matching, n (%)/mean ± SD
| Baseline characteristics | RA+DM (n = 60523) | RA-DM (n = 60523) | P value |
| Age | 69.06 (11.56) | 69.1 (11.60) | 0.986 |
| Gender | |||
| Female | 42031 (69.45) | 41985 (69.37) | 0.774 |
| Race | |||
| White | 40840 (67.48) | 40910 (67.59) | 0.667 |
| Black | 10059 (16.62) | 9997 (16.51) | 0.632 |
| Hispanic | 6368 (10.52) | 6391 (10.55) | 0.830 |
| Asian | 1375 (2.27) | 1384 (2.28) | 0.862 |
| Native | 1196 (1.98) | 1149 (1.89) | 0.327 |
| Other | 685 (1.13) | 692 (1.14) | 0.850 |
| Comorbidities | |||
| Gastro-esophageal reflux disease | 21363 (35.30) | 21363 (35.30) | 1.000 |
| Chronic obstructive pulmonary disease | 7849 (12.97) | 7833 (12.94) | 0.898 |
| Asthma | 6271 (10.36) | 6268 (10.36) | 0.985 |
| Smoking | 5780 (9.55) | 5761 (9.52) | 0.860 |
| Heart failure | 29061 (48.02) | 29049 (48.00) | 0.950 |
| Chronic kidney disease | 20373 (33.66) | 20348 (33.62) | 0.884 |
| Atrial fibrillation | 9868 (16.30) | 9863 (16.30) | 0.975 |
| Ventricular tachycardia | 1065 (1.76) | 1059 (1.75) | 0.913 |
| Hypertension | 53568 (88.51) | 53525 (88.44) | 0.705 |
| Obesity | 19604 (32.39) | 19580 (32.35) | 0.888 |
| Alcohol use | 1132 (1.87) | 1129 (1.87) | 0.966 |
| Steroids use | 5767 (9.53) | 5760 (9.52) | 0.953 |
| Coronary artery disease | 21901 (36.19) | 21890 (36.17) | 0.952 |
Table 3 Primary outcomes after propensity matching, n (%)
| Outcomes | RA+DM (n = 50423) | RA-DM (n = 50423) | P value |
| Interstitial lung diseases | 1360 (2.25) | 672 (1.11) | < 0.001 |
| Usual interstitial pneumonia/pulmonary fibrosis | 840 (1.67) | 227 (0.45) | < 0.001 |
| Non-specific interstitial pneumonia | 494 (0.98) | 133 (0.26) | < 0.001 |
| Eosinophilic lung disease | 18 (0.04) | 78 (0.15) | < 0.001 |
| Respiratory bronchiolitis interstitial lung disease | 8 (0.02) | 5 (0.01) | < 0.001 |
| Cryptogenic organizing pneumonia | 17 (0.03) | 1 (< 0.01) | 0.057 |
| Acute interstitial pneumonitis | 11 (0.02) | 5 (0.01) | < 0.001 |
Table 4 Primary and secondary outcomes odds ratio after multivariate regression
| Outcomes | Odds ratio | P value | 95%CI |
| Interstitial lung diseases | 2.203 | < 0.001 | 1.843-2.219 |
| Usual interstitial pneumonia/pulmonary fibrosis | 3.200 | < 0.001 | 2.800-3.700 |
| Non-specific interstitial pneumonia | 3.500 | < 0.001 | 2.900-4.100 |
| Eosinophilic lung disease | 0.232 | < 0.001 | 0.112-0.415 |
| Respiratory bronchiolitis interstitial lung disease | 1.636 | 0.002 | 0.531-5.036 |
| Cryptogenic organizing pneumonia | 96.040 | 0.06 | 0.860-1072 |
| Acute interstitial pneumonitis | 2.201 | < 0.001 | 0.764-6.335 |
| Acute respiratory distress syndrome | 1.116 | 0.260 | 0.921-1.353 |
| Pneumothorax | 1.848 | < 0.001 | 1.465-2.332 |
| Pleural effusion | 1.028 | 0.49 | 0.959-1.101 |
| Pulmonary arterial hypertension | 1.397 | < 0.001 | 1.331-1.467 |
Table 5 Secondary outcomes after propensity matching, n (%)
| Outcomes | RA+DM (n = 50423) | RA-DM (n = 50423) | P value |
| Acute respiratory distress syndrome | 221 (0.44) | 198 (0.39) | 0.260 |
| Pneumothorax | 203 (0.40) | 110 (0.22) | < 0.001 |
| Pleural effusion | 1694 (3.36) | 1648 (3.27) | 0.49 |
| Pulmonary arterial hypertension | 4141 (8.21) | 2964 (5.88) | < 0.001 |
- Citation: Sutton J, Khattar G, Saliba F, Mourad O, Aoun L, Jdaidani J, Qandil H, Kaspar C, Abu-Baker S, Almardini S, Haddadin F, Bou Sanayeh E, Slobodnick A. Impact of type 2 diabetes mellitus on interstitial lung disease risk in rheumatoid arthritis. World J Clin Cases 2025; 13(33): 110641
- URL: https://www.wjgnet.com/2307-8960/full/v13/i33/110641.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v13.i33.110641
